• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

New BD Plant in Spain Will Add Capacity to Support Vaccination Campaigns


Global med tech BD (Becton, Dickinson and Company) is to build a €165 million (USD $200 million) high-tech manufacturing facility in Zaragoza, Spain. Construction of the new plant will begin in late 2021 and will initially have a workforce of 150 people. By 2030 it is expected to employ up to 600 people.

The new plant ”will produce drug delivery devices, primarily for pharmaceutical companies that supply the European market with drugs in pre-fillable syringes such as vaccines and other biologic drugs,” said Eric Borin, worldwide president of BD Pharmaceutical Systems. It will also ”add needed capacity to support major vaccination campaigns, such as the one currently taking place in response to the COVID-19 pandemic.”

The new site represents a portion of the $1.2 billion USD investment over four years that was announced in December 2020 to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) as part of BD’s 2025 growth strategy.

The new site also continues BD’s commitment to Spain, where it started operations more than 40 years ago and currently has three production plants located in San Agustín de Guadalix, Fraga and Almaraz.